著者

Masunori Matsuzaki Toru Kita Hiroshi Mabuchi Yuji Matsuzawa Noriaki Nakaya Shinichi Oikawa Yasushi Saito Jun Sasaki Kazuaki Shimamoto Hiroshige Itakura the J-LIT Study Group

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

vol.66, no.12, pp.1087-1095, 2002 (Released:2002-11-25)

参考文献数

52

被引用文献数

172 195

---

Hyperlipidemia is a well-established risk factor for primary coronary heart disease (CHD). Although simvastatin is known to lower serum lipid concentrations, the protective effect of such lipid-lowering therapy against primary CHD has not been established in Japanese patients with hypercholesterolemia. The Japan Lipid Intervention Trial was a 6-year, nationwide cohort study of 47,294 patients treated with open-labeled simvastatin (5-10 mg/day) and monitored by physicians under standard clinical conditions. The aim of the study was to determine the relationship between the occurrence of CHD and the serum lipid concentrations during low-dose simvastatin treatment. Simvastatin reduced serum concentrations of total cholesterol (TC), low-density lipoprotein- cholesterol (LDL-C) and triglyceride (TG), by 18.4%, 26.8% and 16.1% on average, respectively, during the treatment period. The risk of coronary events was higher when the average TC concentration was ≥240 mg/dl and the average LDL-C concentration was ≥160 mg/dl. The incidence of coronary events increased in the patients with TG concentration ≥300 mg/dl compared with patients with TG concentration <150 mg/dl. The high-density lipoprotein cholesterol (HDL-C) inversely correlated with the risk of coronary events. The J-curve association was observed between average TC or LDL-C concentrations and total mortality. Malignancy was the most prevalent cause of death. The health of patients should be monitored closely when there is a remarkable decrease in TC and LDL-C concentrations with low-dose statin. A reasonable strategy to prevent coronary events in Japanese hypercholesterolemic patients without prior CHD under low-dose statin treatment might be regulating the serum lipid concentrations to at least <240 mg/dl for TC, <160 mg/dl for LDL-C, <300 mg/dl for TG, and >40 mg/dl for HDL-C. (Circ J 2002; 66: 1087 - 1095)

著者

Tadashi HASE Yumiko KOMINE Shinichi MEGURO Yoko TAKEDA Hidekazu TAKAHASHI Yuji MATSUI Setsujiro INAOKA Yoshihisa KATSURAGI Ichiro TOKIMITSU Hiroyuki SHIMASAKI Hiroshige ITAKURA

出版者

Japan Oil Chemists' Society

雑誌

Journal of Oleo Science (ISSN:13458957)

巻号頁・発行日

vol.50, no.7, pp.599-605, 2001 (Released:2002-06-28)

参考文献数

41

被引用文献数

60 64

---

To examine the anti-obesity effects of tea catechins in humans, a trial study using healthy male subjects (27-47 years). Comprising in equal number a low dose catechin (LDC) group (n=11) and high dose catechin (HDC) group (n=12). The groups were administered catechins at 118.5 mg and 483.0 mg a day for 12 weeks, respectively. At 4 and 12 weeks, effect evaluation was made based on change in weight, body mass index (BMI), waist circumference, body fat ratio and abdominal fat as determined by computed tomography (CT) and triacylglycerol, total cholesterol, free fatty acid, glucose, insulin and total plasminogen activator inhibitor-1 (PAI-1) in serum. In the HDC group, at 12 weeks, weight, BMI, waist circumference, body fat ratio, abdominal fat and total cholesterol, glucose, insulin, PAI-1 in serum were noted to have significantly decreased from values at 0 week. In the LDC group, only weight, BMI and insulin had changed. In the HDC group, BMI had decreased significantly in 25≤BMI subjects compared to 25>BMI subjects. In the 25≤BMI subjects, BMI decreased significantly more in the HDC group. Tea catechins are thus shown here for the first time to have the anti-obesity effects in humans.

著者

Hidenori Arai Akira Yamamoto Yuji Matsuzawa Yasushi Saito Nobuhiro Yamada Shinichi Oikawa Hiroshi Mabuchi Tamio Teramoto Jun Sasaki Noriaki Nakaya Hiroshige Itakura Yuichi Ishikawa Yasuyoshi Ouchi Hiroshi Horibe Nobuo Shirahashi Toru Kita

出版者

一般社団法人 日本動脈硬化学会

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

vol.13, no.4, pp.202-208, 2006 (Released:2006-08-15)

参考文献数

15

被引用文献数

87 126

---

To determine the prevalence of metabolic syndrome in the Japanese general population, we analyzed data from a nationwide survey conducted in 2000. According to the Japanese new diagnostic criteria for metabolic syndrome in 2005, we analyzed 3,264 people aged from 20 to 79 (men, 1,917; women, 1,347) from the total participants. The incidence of metabolic syndrome was 7.8%. Men had a higher incidence (12.1%) than women (1.7%). Most of the women satisfying the criteria were 50 years old or over, while the incidence in men started to rise from their 30s. When we applied the criteria of Adult Treatment Panel III, the incidence was about 3-fold higher. In this population visceral obesity was associated with metabolic abnormalities, such as higher LDL-cholesterol, triglyceride, glucose, and blood pressure and lower HDL-cholesterol. Thus we determined the incidence of metabolic syndrome and each metabolic abnormality in the Japanese general population in 2000 and found an association of visceral obesity with metabolic abnormalities. Intervention to reduce the incidence of metabolic syndrome in Japan is necessary to reduce the risk of cardiovascular disease.

著者

Hiroshige Itakura Mitsuhiro Yokoyama Masunori Matsuzaki Yasushi Saito Hideki Origasa Yuichi Ishikawa Shinichi Oikawa Jun Sasaki Hitoshi Hishida Toru Kita Akira Kitabatake Noriaki Nakaya Toshiie Sakata Kazuyuki Shimada Kunio Shirato Yuji Matsuzawa

出版者

Japan Atherosclerosis Society

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

vol.18, no.2, pp.99-107, 2011 (Released:2011-02-24)

参考文献数

32

被引用文献数

98 188 39

---

Aim: The Japan EPA Lipid Intervention Study (JELIS) was the first prospective randomized clinical trial to demonstrate prevention of coronary events by pure eicosapentaenoic acid (EPA). The aim of this study was to examine the relationships between various plasma fatty acid concentrations and the risk of coronary events in JELIS participants.Methods: In 15,534 participants, we calculated the hazard ratio for major coronary events (sudden cardiac death, fatal or nonfatal myocardial infarction, unstable angina pectoris, and angioplasty/stenting or coronary artery bypass grafting) relative to the on-treatment average level of plasma fatty acids with the Cox proportional hazard model.Results: As a result of EPA intervention, the plasma EPA concentration increased, but the docosahexaenoic acid (DHA) concentration did not. The other fatty acids measured decreased slightly. The higher plasma level of EPA (hazard ratio=0.83, p=0.049, in all participants and hazard ratio=0.71, p=0.018, in the EPA intervention group), but not of DHA, was inversely associated with the risk of major coronary events. The associations between other fatty acids and the risk of major coronary events were not significant. In all JELIS participants, the risk of major coronary events was significantly decreased (20%) in the group with high (150 µg/mL or more) on-treatment plasma EPA concentration compared with that in the low (less than 87 µg/mL) group.Conclusion: The risk of coronary artery disease is influenced by variations in plasma fatty acid composition. Among n-3 polyunsaturated fatty acids, EPA and DHA exhibited differences in the correlation with the risk of major coronary events.

著者

Hidenori Arai Akira Yamamoto Yuji Matsuzawa Yasushi Saito Nobuhiro Yamada Shinichi Oikawa Hiroshi Mabuchi Tamio Teramoto Jun Sasaki Noriaki Nakaya Hiroshige Itakura Yuichi Ishikawa Yasuyoshi Ouchi Hiroshi Horibe Tohru Egashira Hiroaki Hattori Nobuo Shirahashi Toru Kita

出版者

一般社団法人 日本動脈硬化学会

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

vol.12, no.5, pp.240-250, 2005 (Released:2005-10-05)

参考文献数

53

被引用文献数

27 31

---

We studied the association of six common polymorphisms of four genes related to lipid metabolism with serum lipid levels. We selected single-nucleotide polymorphisms (SNPs) in the genes for cholesteryl ester transfer protein (CETP), lipoprotein lipase (LPL), hepatic lipase (LIPC), and apolipoprotein CIII (APOC3), and studied 2267 individuals randomly selected from the participants of Serum Lipid Survey 2000. There was a significant association of CETP polymorphism (D442G, Int14 +1 G → A, and TaqIB), LPL polymorphism (S447X), and LIPC polymorphism (−514 → CT) with HDL-cholesterol levels. We also found a significant association of LPL polymorphism (S447X) and APOC3 polymorphism (SstI) with triglyceride levels. This is the largest database showing the association of common genetic variants in lipid metabolism with serum lipid levels in the general Japanese population. Further study is necessary to elucidate the role of these gene polymorphisms in cardiovascular events.

著者

Tamami Iwamoto Kazuaki Hosoda Reiko Hirano Hideaki Kurata Akiyo Matsumoto Wataru Miki Masumi Kamiyama Hiroshige Itakura Shigeru Yamamoto Kazuo Kondo

出版者

Japan Atherosclerosis Society

雑誌

Journal of Atherosclerosis and Thrombosis (ISSN:13403478)

巻号頁・発行日

vol.7, no.4, pp.216-222, 2000 (Released:2011-09-20)

参考文献数

42

被引用文献数

185 224

---

Marine animals produce astaxanthin which is a carotenoid and antioxidant. In this study we determined the in vitro and ex vivo effects of astaxanthin on LDL oxidation. The oxidation of LDL was measured in a 1 ml reaction system consisting of increasing concentrations of astaxanthin (12.5, 25.0, 50.0 μg/ml), 400 μM V-70 (2, 2'-azobis (4-methoxy-2, 4-dimethylvaleronitrile)), and LDL (70 μg/ml protein). Astaxanthin dose, dependently significantly prolonged the oxidation lag time (31.5, 45.4, 65.0 min) compared with the control (19.9 min). For the ex vivo study 24 volunteers (mean age 28.2 [SD 7.8] years) consumed astaxanthin at doses of 1.8, 3.6, 14.4 and 21.6 mg per day for 14 days. No other changes were made in the diet. Fasting venous blood samples were taken at days 0, +14. LDL lag time was longer (5.0, 26.2, 42.3 and 30.7% respectively) compared with day O after consuming astaxanthin at doses of 1.8, 3.6, 14.4 and 21.6 mg for 14 days compared with day O, but there was no difference in oxidation of LDL between day O (lag time 59.9 + 7.2 min) and day 14 (57.2 ± 6.0 min) in the control group. Our results provide evidence that consumption of marine animals producing astaxanthin inhibits LDL oxidation and possibly therefore contributes to the prevention of atherosclerosis.

著者

Taichi Ishizaki Maki Wakabayashi Hiroyuki Tanimoto Atsuhito Shima Mitsuharu Yabune Osami Kajimoto Hiroshige Itakura

出版者

SOCIETY FOR FREE RADICAL RESEARCH JAPAN

雑誌

Journal of Clinical Biochemistry and Nutrition (ISSN:09120009)

巻号頁・発行日

vol.33, no.3, pp.75-82, 2003 (Released:2010-07-01)

参考文献数

9

被引用文献数

11 10

---

In a placebo-controlled double-blind study, we examined the effects on blood lipids during long-term consumption of mayonnaise containing phytosterolester in Japanese with borderline or mild hyperlipidemia. We also examined the safety of this mayonnaise. Fifty-five subjects were divided into 2 groups, one group of which was given for 3 months 15g/day of a placebo mayonnaise (Placebo), and the other, 15g/day of mayonnaise containing 884mg/day of phytosterolester (MSE) for the same period of time. Hematological testing and confirmation of objective and subjective symptoms were conducted every month. Total cholesterol and LDL cholesterol levels did not change in the Placebo group throughout the study, but they did significantly decrease 1, 2, and 3 months after the start of intake in the MSE group. Significant differences were seen between Placebo group and MSE group in the amount of changes in total cholesterol 1, 2, and 3 months after the start of intake, and in LDL cholesterol 1 and 2 months after the start of intake. Furthermore, the results of hematological testing other than for blood lipids and physician interview revealed no adverse events caused by long-term consumption of the test foods. We thus concluded mayonnaise containing phytosterolester to be safe and to lower total serum cholesterol and LDL cholesterol levels.

著者

Hiroshi Mabuchi Toru Kita Masunori Matsuzaki Yuji Matsuzawa Noriaki Nakaya Shinichi Oikawa Yasushi Saito Jun Sasaki Kazuaki Shimamoto Hiroshige Itakura the J-LIT Study Group

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

vol.66, no.12, pp.1096-1100, 2002 (Released:2002-11-25)

参考文献数

26

被引用文献数

84 103

---

Hyperlipidemia is primarily implicated in the progression of coronary heart disease (CHD) and its treatment is essential for patients with a history of CHD. Statins such as simvastatin, the lipid-lowering agents, are well-known for their ability to normalize patient's serum lipid levels. The Japan Lipid Intervention Trial study of simvastatin is the first nationwide investigation of the relationship between serum lipid levels and the development of CHD in Japanese patients with hypercholesterolemia. Of 5,127 patients, exclusively with a history of documented CHD at enrollment, 4,673 were treated with open-labeled simvastatin at an initial dose of 5-10 mg/day and were monitored for 6 years. The risk of coronary events tended to be higher in patients with a serum total cholesterol (TC) ≥240 mg/dl compared with total cholesterol <240 mg/dl. The concentration of low-density lipoprotein cholesterol (LDL-C) positively correlated and that of high-density lipoprotein cholesterol (HDL-C) inversely correlated with the risk of CHD. Each 10 mg/dl decrease in LDL-C and each 10 mg/dl increase in HDL-C concentration reduced the risk of CHD by 8.0% (95% confidence interval 3.8-12.0) and 28.3% (95% CI 13.9-40.3), respectively. A reasonable therapeutic strategy to reduce CHD progression in patients with prior CHD under low-dose statin treatment might be regulating the serum LDL-C concentration to at least <120 mg/dl and HDL-C >40 mg/dl, respectively. (Circ J 2002; 66: 1096 - 1100)

著者

Shinichi MEGURO Tomohito MIZUNO Kouji ONIZAWA Keiko KAWASAKI Hideaki NAKAGIRI Yumiko KOMINE Junko SUZUKI Yuji MATSUI Tadashi HASE Ichiro TOKIMITSU Hiroyuki SHIMASAKI Hiroshige ITAKURA

出版者

Japan Oil Chemists' Society

雑誌

Journal of Oleo Science (ISSN:13458957)

巻号頁・発行日

vol.50, no.7, pp.593-598, 2001 (Released:2002-06-28)

参考文献数

29

被引用文献数

14 16 17

---

Examination was made of the effects of tea catechins (TC) on diet-induced obesity. Exposure to high-fat-diet (30% fat) in C57BL/6J mice for 4 weeks induced significant increase in body weight, visceral fat (epididymal, mesenteric, retroperitoneal, perinephric) weight and plasma concentrations of glucose, triacylglycerol and leptin, compared to low-fat diet (5% fat). Treatment with 0.1%TC (high-fat diet +0.1%TC group) had little effect on diet-induced obesity. Relative to high-fat diet and 0.1%TC treatment, 0.5%TC treatment (high-fat diet +0.5%TC group) was noted to bring about significant decrease in body weight, visceral, fat weights and plasma leptin. Lipid absorption rate was the same with the high fat diet and 0.5%TC treatment. An oral soluble starch and sucrose (SS-S) tolerance test was conducted on C57BL/6J mice to evaluate the effects of TC to sugar absorption. When the ratio of TC to sum of SS-S was the same as that in the diet composition for the 0.5%TC treatment, the plasma glucose level showed no response. These results demonstrate for the first time TC to have antiobesity effects on diet-induced obesity in mice, and suggest these effects to be exerted through a mechanism that would not involve inhibition of intestinal absorption of sugar and lipid.

著者

Tomonori NAGAO Shinichi MEGURO Satoko SOGA Atsuko OTSUKA Kazuichi TOMONOBU Shinichi FUMOTO Akiro CHIKAMA Kenta MORI Masayuki YUZAWA Hiroyuki WATANABE Tadashi HASE Yukitaka TANAKA Ichiro TOKIMITSU Hiroyuki SHIMASAKI Hiroshige ITAKURA

出版者

Japan Oil Chemists' Society

雑誌

Journal of Oleo Science (ISSN:13458957)

巻号頁・発行日

vol.50, no.9, pp.717-728, 2001 (Released:2002-06-28)

参考文献数

34

被引用文献数

33 36

---

The body fat reducing effect of tea catechins was previously confirmed in humans. The effects of tea catechins for reducing body fat were thus studied as basis for actual application. Three experiments on healthy male adults (n=82) were conducted to determine the effects of long-term tea catechins administration on body fat and biochemical blood parameters. First experiment: tea catechins were given as oolong tea-like beverage for 12 weeks. In 600 and 900 mg groups, visceral fat was significantly loss than in the control (600 mg group p=0.0317, 900 mg group p=0.0098). The effects were more pronounced at greater of tea catechins administration. No significant changes in biochemical blood parameters including fat-soluble vitamins were detected. Second experiment : oolong tea-like beverage containing tea catechins at nearly same amounts on in the 600 mg group was given for 20 weeks. Abdominal fat, including visceral fat, was significantly loss than in the control (total fat area p<0.0001, visceral fat area p=0.0004, subcutaneous fat area p=0.0001). Plasma PAI-1 was also significantly decreased (p=0.0080). Third experiment : green tea-like (GT group) and oolong tea-like (OT group) beverages containing approximately 540 mg tea catechins were given for 12 weeks. In the two groups, visceral fat was significantly loss than in the control (GT group p=0.0284, OT group p=0.0095) and the effects of two beverages were similar. Long-term tea catechins administration at 500 to 600 mg/day in humans would thus appear to reduce body fat without influencing fat-soluble vitamins, of which the absorption may be inhibited, and various serum and plasma indices regardless of the kind of beverages.